JP2005504093A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005504093A5 JP2005504093A5 JP2003530286A JP2003530286A JP2005504093A5 JP 2005504093 A5 JP2005504093 A5 JP 2005504093A5 JP 2003530286 A JP2003530286 A JP 2003530286A JP 2003530286 A JP2003530286 A JP 2003530286A JP 2005504093 A5 JP2005504093 A5 JP 2005504093A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- pyrazol
- pyridin
- butylphenyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 substituted pyrazole compound Chemical class 0.000 claims 150
- 125000001072 heteroaryl group Chemical group 0.000 claims 76
- 125000000217 alkyl group Chemical group 0.000 claims 70
- 125000003710 aryl alkyl group Chemical group 0.000 claims 62
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 60
- PQFMNVGMJJMLAE-QMMMGPOBSA-N L-tyrosinamide Chemical compound NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PQFMNVGMJJMLAE-QMMMGPOBSA-N 0.000 claims 48
- 229910052739 hydrogen Inorganic materials 0.000 claims 46
- 239000001257 hydrogen Substances 0.000 claims 46
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 44
- 125000000547 substituted alkyl group Chemical group 0.000 claims 44
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 42
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 42
- 239000008194 pharmaceutical composition Substances 0.000 claims 38
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 34
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 28
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 24
- 125000004414 alkyl thio group Chemical group 0.000 claims 22
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 22
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 22
- 150000003973 alkyl amines Chemical class 0.000 claims 20
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 18
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 16
- 125000002723 alicyclic group Chemical group 0.000 claims 16
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 16
- 150000001413 amino acids Chemical class 0.000 claims 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 229910052736 halogen Inorganic materials 0.000 claims 16
- 150000002367 halogens Chemical class 0.000 claims 16
- 125000004474 heteroalkylene group Chemical group 0.000 claims 16
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 16
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 16
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 14
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 14
- 125000006491 4-t-butyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 12
- 125000002947 alkylene group Chemical group 0.000 claims 12
- 125000004076 pyridyl group Chemical group 0.000 claims 12
- 125000004450 alkenylene group Chemical group 0.000 claims 10
- 125000004419 alkynylene group Chemical group 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 10
- 241000124008 Mammalia Species 0.000 claims 9
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 8
- 150000003862 amino acid derivatives Chemical class 0.000 claims 8
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 125000004122 cyclic group Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- YMTDQFJUGKJUAE-VIFPVBQESA-N (2s)-2-(hydroxymethylamino)-3-phenylpropanamide Chemical compound OCN[C@H](C(=O)N)CC1=CC=CC=C1 YMTDQFJUGKJUAE-VIFPVBQESA-N 0.000 claims 4
- MGOGKPMIZGEGOZ-REOHCLBHSA-N (2s)-2-amino-3-hydroxypropanamide Chemical compound OC[C@H](N)C(N)=O MGOGKPMIZGEGOZ-REOHCLBHSA-N 0.000 claims 4
- PZUOEYPTQJILHP-GBXIJSLDSA-N (2s,3r)-2-amino-3-hydroxybutanamide Chemical compound C[C@@H](O)[C@H](N)C(N)=O PZUOEYPTQJILHP-GBXIJSLDSA-N 0.000 claims 4
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 4
- TUEXMSFXLWQHFG-UHFFFAOYSA-N 4-[2-[3-[2-(4-tert-butylphenyl)-5-pyridin-4-ylpyrazol-3-yl]propylamino]ethyl]phenol Chemical compound C1=CC(C(C)(C)C)=CC=C1N1C(CCCNCCC=2C=CC(O)=CC=2)=CC(C=2C=CN=CC=2)=N1 TUEXMSFXLWQHFG-UHFFFAOYSA-N 0.000 claims 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 4
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 4
- 125000002877 alkyl aryl group Chemical group 0.000 claims 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 4
- 125000002541 furyl group Chemical group 0.000 claims 4
- 125000004404 heteroalkyl group Chemical group 0.000 claims 4
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 4
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 4
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 4
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 4
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims 4
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims 4
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000005556 thienylene group Chemical group 0.000 claims 4
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- FZFDWNSNLNIDTC-UHFFFAOYSA-N 4-[2-[4-[[2-(4-tert-butylphenyl)-5-pyridin-4-ylpyrazol-3-yl]amino]butylamino]ethyl]phenol Chemical compound C1=CC(C(C)(C)C)=CC=C1N1C(NCCCCNCCC=2C=CC(O)=CC=2)=CC(C=2C=CN=CC=2)=N1 FZFDWNSNLNIDTC-UHFFFAOYSA-N 0.000 claims 2
- FMMHXFMDUAUIIT-UHFFFAOYSA-N 5-[2-(4-tert-butylphenyl)-5-pyridin-3-ylpyrazol-3-yl]pentanoic acid Chemical compound C1=CC(C(C)(C)C)=CC=C1N1C(CCCCC(O)=O)=CC(C=2C=NC=CC=2)=N1 FMMHXFMDUAUIIT-UHFFFAOYSA-N 0.000 claims 2
- LZSJMMLWYRJDOA-UHFFFAOYSA-N 5-[2-(4-tert-butylphenyl)-5-pyridin-4-ylpyrazol-3-yl]pentanoic acid Chemical compound C1=CC(C(C)(C)C)=CC=C1N1C(CCCCC(O)=O)=CC(C=2C=CN=CC=2)=N1 LZSJMMLWYRJDOA-UHFFFAOYSA-N 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 2
- 206010002261 Androgen deficiency Diseases 0.000 claims 2
- 206010006895 Cachexia Diseases 0.000 claims 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 2
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000006165 cyclic alkyl group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 201000006938 muscular dystrophy Diseases 0.000 claims 2
- BQAGGQPHWTYHJH-LJAQVGFWSA-N n-[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]-6-[2-(4-tert-butylphenyl)-5-pyridin-2-ylpyrazol-3-yl]-n-methylhexanamide Chemical compound O=C([C@@H](N)CC=1C=CC(O)=CC=1)N(C)C(=O)CCCCCC1=CC(C=2N=CC=CC=2)=NN1C1=CC=C(C(C)(C)C)C=C1 BQAGGQPHWTYHJH-LJAQVGFWSA-N 0.000 claims 2
- PMRGBQGHMSTEFL-QFIPXVFZSA-N n-[(2s)-2-amino-3-hydroxypropanoyl]-6-[2-(4-propan-2-ylphenyl)-5-pyridin-2-ylpyrazol-3-yl]hexanamide Chemical compound C1=CC(C(C)C)=CC=C1N1C(CCCCCC(=O)NC(=O)[C@@H](N)CO)=CC(C=2N=CC=CC=2)=N1 PMRGBQGHMSTEFL-QFIPXVFZSA-N 0.000 claims 2
- DZFSKNAODBHZEK-QFIPXVFZSA-N n-[(2s)-2-amino-3-hydroxypropanoyl]-6-[2-(4-tert-butylphenyl)-5-pyridin-2-ylpyrazol-3-yl]hexanamide Chemical compound C1=CC(C(C)(C)C)=CC=C1N1C(CCCCCC(=O)NC(=O)[C@@H](N)CO)=CC(C=2N=CC=CC=2)=N1 DZFSKNAODBHZEK-QFIPXVFZSA-N 0.000 claims 2
- 230000003287 optical effect Effects 0.000 claims 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 2
- 230000035935 pregnancy Effects 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 230000021595 spermatogenesis Effects 0.000 claims 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 0 **C(C(*)C(*)=N1)N*1I Chemical compound **C(C(*)C(*)=N1)N*1I 0.000 description 11
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32547001P | 2001-09-27 | 2001-09-27 | |
| PCT/US2002/030801 WO2003026649A1 (en) | 2001-09-27 | 2002-09-27 | Methods of increasing endogenous testosterone levels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005504093A JP2005504093A (ja) | 2005-02-10 |
| JP2005504093A5 true JP2005504093A5 (enExample) | 2006-01-05 |
Family
ID=23268011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003530286A Pending JP2005504093A (ja) | 2001-09-27 | 2002-09-27 | 内因性テストステロンレベルの増加方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20040198799A1 (enExample) |
| EP (1) | EP1441724B8 (enExample) |
| JP (1) | JP2005504093A (enExample) |
| AT (1) | ATE372114T1 (enExample) |
| AU (1) | AU2002330120B2 (enExample) |
| CA (1) | CA2458661A1 (enExample) |
| DE (1) | DE60222286T2 (enExample) |
| DK (1) | DK1441724T3 (enExample) |
| ES (1) | ES2289143T3 (enExample) |
| IL (1) | IL161047A0 (enExample) |
| PT (1) | PT1441724E (enExample) |
| WO (1) | WO2003026649A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6914069B2 (en) * | 2000-05-19 | 2005-07-05 | Applied Research Systems Ars Holding N.V. | Pharmaceutically active compounds and methods of use |
| WO2004016592A1 (en) * | 2002-08-14 | 2004-02-26 | Ppd Discovery, Inc. | Prenylation inhibitors and methods of their synthesis and use |
| US8241664B2 (en) | 2005-04-15 | 2012-08-14 | Clarus Therapeutics, Inc | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
| US8492369B2 (en) | 2010-04-12 | 2013-07-23 | Clarus Therapeutics Inc | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
| MX2008000141A (es) * | 2005-06-27 | 2008-04-07 | Exelixis Inc | Moduladores de lxr basados en imidazol. |
| JP5110478B2 (ja) | 2006-06-23 | 2012-12-26 | 株式会社Ｊ−オイルミルズ | テストステロン増加剤 |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| MY161598A (en) * | 2009-01-30 | 2017-04-28 | Glaxosmithkline Llc | Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride |
| WO2011161615A1 (en) | 2010-06-24 | 2011-12-29 | Ranbaxy Laboratories Limited | 5-lipoxygenase inhibitors |
| WO2011161645A1 (en) | 2010-06-25 | 2011-12-29 | Ranbaxy Laboratories Limited | 5-lipoxygenase inhibitors |
| JP5860459B2 (ja) | 2010-06-30 | 2016-02-16 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | ｓＧＣ刺激薬 |
| ES2572803T3 (es) | 2010-11-09 | 2016-06-02 | Ironwood Pharmaceuticals, Inc. | Estimuladores de GCs |
| US9139564B2 (en) | 2011-12-27 | 2015-09-22 | Ironwood Pharmaceuticals, Inc. | 2-benzyl, 3-(pyrimidin-2-yl) substituted pyrazoles useful as sGC stimulators |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2665898B1 (fr) * | 1990-08-20 | 1994-03-11 | Sanofi | Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| DE4039733A1 (de) * | 1990-12-13 | 1992-06-17 | Basf Ag | Substituierte 5-aminopyrazole |
| BR9307664A (pt) * | 1992-12-17 | 1999-06-29 | Pfizer | Pirazóis substituídos como antagonistas |
| KR960705808A (ko) * | 1993-11-09 | 1996-11-08 | 조셉 에프. 디프리마 | 성장 호르몬의 방출을 촉진시키는 피페리딘, 피롤리딘 및 헥사하이드로-1H-아제핀(Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone) |
| US5869688A (en) * | 1994-07-20 | 1999-02-09 | Monsanto Company | Preparation of substituted 3-aryl-5-haloalkyl-pyrazoles having herbicidal activity |
| CA2288787A1 (en) * | 1997-05-22 | 1998-11-26 | G.D. Searle And Co. | Pyrazole derivatives as p38 kinase inhibitors |
| CA2308428A1 (en) * | 1997-11-03 | 1999-05-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
| ATE301129T1 (de) * | 1999-05-04 | 2005-08-15 | Strakan Int Ltd | Androgen glykoside und die androgenische aktivität davon |
| US6914069B2 (en) * | 2000-05-19 | 2005-07-05 | Applied Research Systems Ars Holding N.V. | Pharmaceutically active compounds and methods of use |
| CZ2003468A3 (cs) * | 2000-08-31 | 2004-05-12 | Pfizeráproductsáinc | Deriváty pyrazolu a jejich použití jako inhibitorů proteinkinázy |
-
2002
- 2002-09-27 JP JP2003530286A patent/JP2005504093A/ja active Pending
- 2002-09-27 AT AT02766382T patent/ATE372114T1/de not_active IP Right Cessation
- 2002-09-27 US US10/489,863 patent/US20040198799A1/en not_active Abandoned
- 2002-09-27 EP EP02766382A patent/EP1441724B8/en not_active Expired - Lifetime
- 2002-09-27 DK DK02766382T patent/DK1441724T3/da active
- 2002-09-27 DE DE60222286T patent/DE60222286T2/de not_active Expired - Fee Related
- 2002-09-27 CA CA002458661A patent/CA2458661A1/en not_active Abandoned
- 2002-09-27 WO PCT/US2002/030801 patent/WO2003026649A1/en not_active Ceased
- 2002-09-27 ES ES02766382T patent/ES2289143T3/es not_active Expired - Lifetime
- 2002-09-27 IL IL16104702A patent/IL161047A0/xx unknown
- 2002-09-27 PT PT02766382T patent/PT1441724E/pt unknown
- 2002-09-27 AU AU2002330120A patent/AU2002330120B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI429436B (zh) | 使用生長激素促泌素治療或預防嘔吐之方法 | |
| JP2008502700A5 (enExample) | ||
| JP2005504093A5 (enExample) | ||
| JP2014511869A5 (enExample) | ||
| JP2009528354A5 (enExample) | ||
| RU2000131184A (ru) | Соединения, обладающие свойствами, способствующими выделению гормона роста | |
| JP2010523644A5 (enExample) | ||
| US20060258709A1 (en) | Combination of a cb1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity | |
| JP2004512279A (ja) | Ｃｂ１受容体アンタゴニストおよびシブトラミンの組み合わせ、それらからなる医薬組成物、および肥満の治療におけるそれらの使用 | |
| JP2010505881A5 (enExample) | ||
| JP6668329B2 (ja) | 新規オキサジアゾール誘導体及びこれを含有する医薬 | |
| RU2011149360A (ru) | Замещенные фенилмочевины и фениламиды в качестве лигандов ваниллоидных рецепторов | |
| RU2002132385A (ru) | Новые соединения | |
| CA2463102A1 (en) | Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors | |
| RU2010142937A (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ПИПЕРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ СТЕАРОИЛ-КоА ДЕСАТУРАЗЫ | |
| JP2011518774A5 (enExample) | ||
| WO2006076575B1 (en) | Substituted biaryl compounds as factor xia inhibitors | |
| RU2009141619A (ru) | Соединения, обладающие противораковой активностью | |
| CA2436526A1 (en) | Heterocyclic sulfonamide inhibitors of beta amyloid production | |
| RU2009139087A (ru) | Производные 8-оксихинолина в качестве модуляторов рецептора в2 брадикинина | |
| CA2329881A1 (en) | Compounds with growth hormone releasing properties | |
| JP2009507011A5 (enExample) | ||
| JP2006022108A5 (enExample) | ||
| CA2640080A1 (en) | Compositions and methods for the treatment of ophthalmic disease | |
| RU2009118254A (ru) | Фенилацетамиды в качестве ингибиторов протеинкиназ |